Renewal of licensing fee for the transgenic mouse strain, B-hIL2RA

The National Institutes of Health, through the Molecular Imaging Branch of the Center for Cancer Research, is seeking to renew the licensing agreement for the B-hIL2RA transgenic mouse strain to support ongoing pre-clinical research in photoimmunotherapy. This mouse model expresses the human form of the IL2RA protein, enabling researchers to evaluate therapeutic antibodies and other treatment modalities that are specifically designed for human use, ensuring translational relevance in studies aimed at selectively eliminating regulatory T cells that suppress anti-cancer immune responses. The renewal is critical to maintaining access to this indispensable biological resource, which underpins the branch’s efforts to enhance immune activation against tumors through targeted light-activated therapies. The solicitation, numbered 75N98026Q00467, is a presolicitation posted on May 28, 2026, with a response deadline of June 8, 2026, and is issued under NAICS code 51321 without any set-aside preferences. The place of performance is specified as Bethesda, Maryland, 20892, with John Burton listed as the primary point of contact. While the exact financial terms, delivery schedule, or contract duration are not outlined, the renewal is framed as a necessary administrative action to sustain a proven and vital research capability. No formal contract clauses, evaluation criteria, packaging requirements, or submission instructions beyond the deadline are provided, indicating a streamlined process focused solely on the continuation of an existing licensing arrangement essential to the research mission.